Kari Alitalo
Impact in
- Oncology top 0.01%
- Lymphatic System and Diseases
- Cancer Cells and Metastasis
- Immunology and Allergy top 0.02%
- Cell Adhesion Molecules Research
Papers in
-
- Angiogenesis and VEGF in Cancer 296
- Oncology 366
- Lymphatic System and Diseases 277
- Vascular Tumors and Angiosarcomas 44
- Co-authors
- Tuomas Tammela (37 shared papers)Michael Jeltsch (47 shared papers)Seppo Ylä‐Herttuala (79 shared papers)Marika J. Karkkainen (29 shared papers)Taija Mäkinen (37 shared papers)Terhi Kärpänen (27 shared papers)Ralf H. Adams (8 shared papers)Arja Kaipainen (20 shared papers)
- Journals
- Blood (38 papers)Proceedings of the National Academy of Sciences (28 papers)Circulation Research (24 papers)Cancer Research (24 papers)Molecular and Cellular Biology (24 papers)
- Partner nations
- FinlandUnited StatesSweden
In The Last Decade
Kari Alitalo
716 papers receiving 96.0k citations
Kari Alitalo's Hit Papers
Peers
Comparison fields: 5 of 183
- Oncology 45.1k
- Immunology and Allergy 4.8k
- Cancer Research 11.8k
- Molecular Biology 54.9k
- Cell Biology 8.5k
Countries citing papers authored by Kari Alitalo
This map shows the geographic impact of Kari Alitalo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kari Alitalo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kari Alitalo more than expected).
Fields of papers citing papers by Kari Alitalo
This network shows the impact of papers produced by Kari Alitalo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kari Alitalo. The network helps show where Kari Alitalo may publish in the future.
Co-authors
The 25 scholars most cited alongside Kari Alitalo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 724 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia Hit paper breakdown → | 2003 | 2308 |
| 2 | A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules Hit paper breakdown → | 2015 | 1641 |
| 3 | Molecular regulation of angiogenesis and lymphangiogenesis Hit paper breakdown → | 2007 | 1621 |
| 4 | Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis Hit paper breakdown → | 2001 | 1497 |
| 5 | A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. Hit paper breakdown → | 1996 | 1439 |
| 6 | Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour Hit paper breakdown → | 1983 | 1218 |
| 7 | Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Hit paper breakdown → | 1995 | 1186 |
| 8 | Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system Hit paper breakdown → | 2009 | 1158 |
| 9 | Lymphangiogenesis: Molecular Mechanisms and Future Promise Hit paper breakdown → | 2010 | 1155 |
| 10 | Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins Hit paper breakdown → | 2003 | 1129 |
| 11 | Hyperplasia of Lymphatic Vessels in VEGF-C Transgenic Mice Hit paper breakdown → | 1997 | 1086 |
| 12 | Lymphangiogenesis in development and human disease Hit paper breakdown → | 2005 | 1031 |
| 13 | Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Hit paper breakdown → | 1998 | 1007 |
| 14 | Angiosarcomas Express Mixed Endothelial Phenotypes of Blood and Lymphatic Capillaries Hit paper breakdown → | 1999 | 954 |
| 15 | Clinical applications of angiogenic growth factors and their inhibitors Hit paper breakdown → | 1999 | 875 |
| 16 | The lymphatic vasculature in disease Hit paper breakdown → | 2011 | 757 |
| 17 | Copy number variation and selection during reprogramming to pluripotency Hit paper breakdown → | 2011 | 739 |
| 18 | Cardiovascular Failure in Mouse Embryos Deficient in VEGF Receptor-3 Hit paper breakdown → | 1998 | 704 |
| 19 | Homogeneously staining chromosomal regions contain amplified copies of an abundantly expressed cellular oncogene (c-myc) in malignant neuroendocrine cells from a human colon carcinoma. Hit paper breakdown → | 1983 | 701 |
| 20 | The biology of vascular endothelial growth factors Hit paper breakdown → | 2005 | 692 |
About Kari Alitalo
Kari Alitalo is a scholar working on Molecular Biology, Oncology, Cancer Research, Surgery and Cell Biology, having authored 724 papers that have together received 99.5k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (296 papers), Lymphatic System and Diseases (277 papers), Cell Adhesion Molecules Research (55 papers), Axon Guidance and Neuronal Signaling (51 papers), Sympathectomy and Hyperhidrosis Treatments (47 papers), Vascular Tumors and Angiosarcomas (44 papers), Vascular Malformations and Hemangiomas (41 papers) and Cancer, Hypoxia, and Metabolism (37 papers). The work is most often cited by research in Oncology (45.1k citations), Immunology and Allergy (4.8k citations), Cancer Research (11.8k citations), Molecular Biology (54.9k citations) and Cell Biology (8.5k citations). Kari Alitalo has collaborated with scholars based in Finland, United States and Sweden. Frequent co-authors include Tuomas Tammela, Michael Jeltsch, Seppo Ylä‐Herttuala, Marika J. Karkkainen, Taija Mäkinen, Terhi Kärpänen, Ralf H. Adams, Arja Kaipainen, Tatiana V. Petrova and Vladimir Joukov. Their work appears in journals such as Blood, Proceedings of the National Academy of Sciences, Circulation Research, Cancer Research and Molecular and Cellular Biology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.